Insulin Aspart: all 231 studies that test it

Page 2 of 3. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.

• Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin PumpCompletedNCT02546401Phase 3
• A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and SafetyCompletedNCT02491528Phase 3
• Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin AspartCompletedNCT02462161Phase 1
• A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes MellitusCompletedNCT02419859Not applicable
• Normal Versus Dual Wave Insulin Bolus for High-protein FoodCompletedNCT02276859Phase 4
• Insulin Degludec and Symptomatic Nocturnal HypoglycaemiaCompletedNCT02192450Phase 4
• Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin TherapyWithdrawnNCT02144441Not applicable
• A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT02131246Phase 1
• Validation of the Artificial Pancreas Diabeloop Algorithm in the HospitalCompletedNCT02101229Phase 2/3
• A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy SubjectsCompletedNCT02089451Phase 1
• Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes MellitusCompletedNCT02036372Not applicable
• A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 DiabetesCompletedNCT02035371Phase 1
• A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT02033239Phase 1
• A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 DiabetesCompletedNCT02003677Phase 1
• A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 DiabetesCompletedNCT01992588Phase 1
• Insulin by Jet-injection for Hyperglycemia in DiabetesCompletedNCT01947556Not applicable
• A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 DiabetesCompletedNCT01934712Phase 1
• A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 DiabetesCompletedNCT01924637Phase 1
• Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy SubjectsCompletedNCT01868581Phase 1
• Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 DiabetesCompletedNCT01868568Phase 1
• Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With DiabetesCompletedNCT01865305Phase 1
• A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 DiabetesCompletedNCT01773798Phase 1
• Safety and Efficacy of Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT01707134Phase 3
• Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 DiabetesCompletedNCT01704378Phase 4
• Comparison of Two Insulin Aspart Formulations in Healthy VolunteersCompletedNCT01698697Phase 1
• Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 DiabetesCompletedNCT01697631Phase 4
• A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 DiabetesCompletedNCT01682902Phase 1
• Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 DiabetesCompletedNCT01650129Phase 3
• Safety and Efficacy of Insulin Aspart in Type 2 DiabetesCompletedNCT01649570Phase 4
• Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese SubjectsCompletedNCT01620437Phase 1
• Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy VolunteersCompletedNCT01620333Phase 1
• A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 DiabetesCompletedNCT01618188Phase 1
• A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 DiabetesCompletedNCT01590836Phase 1
• Effects of Short-term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes PatientsStatus unknownNCT01588743Not applicable
• Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy VolunteersCompletedNCT01538511Phase 1
• Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT01536028Phase 1
• Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)CompletedNCT01530048Phase 1
• Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy SubjectsCompletedNCT01527656Phase 1
• Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy SubjectsCompletedNCT01527643Phase 1
• Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese SubjectsCompletedNCT01527630Phase 1
• Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male SubjectsCompletedNCT01527565Phase 1
• Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male SubjectsCompletedNCT01527552Phase 1
• Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 DiabetesCompletedNCT01526980Phase 2
• Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 DiabetesCompletedNCT01526941Phase 1
• Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 DiabetesCompletedNCT01524809Phase 1
• Comparison of Two Formulations of Biphasic Insulin Aspart 70CompletedNCT01523041Phase 1
• Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy SubjectsCompletedNCT01520831Phase 1
• Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With DiabetesCompletedNCT01520818Phase 3
• Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 DiabetesCompletedNCT01486940Phase 3
• Comparison of Insulin Aspart Produced by Current Process and the NN2000 ProcessCompletedNCT01486914Phase 1
• A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 DiabetesCompletedNCT01469143Phase 1
• Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 DiabetesCompletedNCT01467401Phase 4
• Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 DiabetesCompletedNCT01467375Phase 3
• Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 DiabetesCompletedNCT01467323Phase 3
• Safety and Efficacy of Insulin Aspart in Children With Type 1 DiabetesCompletedNCT01467141Phase 4
• Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 DiabetesCompletedNCT01464099Phase 1
• A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 DiabetesCompletedNCT01455142Phase 1
• A Trial to Investigate Efficacy and Usability of Published Best Practice to Control GlycaemiaCompletedNCT01407289Phase 4
• Investigation of the Impact of Different Application Volumes of Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT01399346Phase 1
• A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1CompletedNCT01296438Phase 1
• Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 DiabetesCompletedNCT01269606Phase 1
• Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese SubjectsCompletedNCT01242826Phase 1
• Insulin-like Growth Factor (IGF-I) in Hemodialysis PatientsCompletedNCT01209403Phase 4
• A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 DiabetesCompletedNCT01174303Phase 1
• Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT01173926Phase 1
• Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin AspartCompletedNCT01159353Phase 1
• A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 DiabetesCompletedNCT01138488Phase 1
• A Trial Investigating the Effect of NN5401 in Subjects With Type 2 DiabetesCompletedNCT01134224Phase 1
• A Comparison Between Two Formulations of NN5401 in Healthy SubjectsCompletedNCT01125553Phase 1
• A Trial Investigating NN1218 in Subjects With Type 1 DiabetesCompletedNCT01121289Phase 1
• A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 DiabetesCompletedNCT01121276Phase 1
• Effect of NN5401 in Japanese Subjects With Type 1 DiabetesCompletedNCT01051102Phase 1
• Investigation of the Response Relationship of NN5401 in Type 1 DiabeticsCompletedNCT00993096Phase 1
• Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 DiabeticsCompletedNCT00992537Phase 1
• Expanded PK and PD of Insulin Glulisine Versus Insulin Aspart in Healthy VolunteersCompletedNCT00969592Phase 1
• Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 DiabetesCompletedNCT00832182Phase 3
• Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With Non-insulin-dependent Diabetes Mellitus (NIDDM)CompletedNCT00771693Phase 4
• Insulin Effects on Metabolism and Cardiovascular Function in Type 2 DiabetesStatus unknownNCT00747409Phase 4
• Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 DiabetesCompletedNCT00725036Phase 3
• Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 DiabetesCompletedNCT00676819Phase 4
• Management of Hyperglycemia in the ER: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual CareWithdrawnNCT00663624Phase 4
• The Copenhagen Insulin and Metformin Therapy TrialCompletedNCT00657943Phase 4
• Treatment of Impaired Glucose Tolerance in PregnancyCompletedNCT00625781Not applicable
• Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 DiabetesCompletedNCT00624364Phase 4
• Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 DiabetesCompletedNCT00619697Phase 4
• Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 DiabetesCompletedNCT00617565Phase 3
• Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 DiabetesCompletedNCT00612599Phase 3
• Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 DiabetesCompletedNCT00605111Phase 4
• Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 DiabetesCompletedNCT00605020Phase 3
• Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 DiabetesCompletedNCT00604656Phase 3
• Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 DiabetesCompletedNCT00600626Phase 3
• Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 DiabetesCompletedNCT00600366Phase 4
• Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD TherapyCompletedNCT00598793Phase 3
• Human Insulin NPH and Insulin Aspart in Type 1 DiabetesCompletedNCT00597233Phase 4
• Efficacy and Safety of Insulin Detemir in Type 1 DiabetesCompletedNCT00595374Phase 3
• Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 DiabetesCompletedNCT00593255Phase 4
• Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 DiabetesCompletedNCT00592969Phase 4
• Initiation of Insulin Aspart in Type 2 DiabetesCompletedNCT00572806Phase 4
• Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 DiabetesCompletedNCT00571935Phase 4
• Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 DiabetesCompletedNCT00564668Phase 3

← Insulin Aspart overview